Identification of patients at high risk of secondary extramedullary multiple myeloma development

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10434500" target="_blank" >RIV/00669806:_____/22:10434500 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/22:E0109456 RIV/65269705:_____/22:00075995 RIV/00064173:_____/22:43922541 RIV/00098892:_____/22:10157299 a 7 dalších

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=exWLn5lRgT" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=exWLn5lRgT</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/bjh.17925" target="_blank" >10.1111/bjh.17925</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Identification of patients at high risk of secondary extramedullary multiple myeloma development

Popis výsledku v původním jazyce

Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [&lt;65 years; odds ratio (OR) 4 center dot 38, 95% confidence interval (CI): 2 center dot 46-7 center dot 80, P &lt; 0 center dot 0001], high lactate dehydrogenase (LDH) levels (&gt;5 mu kat/l; OR 2 center dot 07, 95% CI: 1 center dot 51-2 center dot 84, P &lt; 0 center dot 0001), extensive osteolytic activity (OR 2 center dot 21, 95% CI: 1 center dot 54-3 center dot 15, P &lt; 0 center dot 001), and immunoglobulin A (IgA; OR 1 center dot 53, 95% CI: 1 center dot 11-2 center dot 11, P = 0 center dot 009) or the non-secretory type of MM (OR 2 center dot 83; 95% CI: 1 center dot 32-6 center dot 04, P = 0 center dot 007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression-free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13 center dot 8 months (95% CI: 11 center dot 4-16 center dot 3) vs 18 center dot 8 months (95% CI: 17 center dot 7-19 center dot 9), P = 0 center dot 006; mOS: 26 center dot 7 months (95% CI: 18 center dot 1-35 center dot 4) vs 58 center dot 7 months (95% CI: 54 center dot 8-62 center dot 6), P &lt; 0 center dot 001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.

Název v anglickém jazyce

Identification of patients at high risk of secondary extramedullary multiple myeloma development

Popis výsledku anglicky

Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [&lt;65 years; odds ratio (OR) 4 center dot 38, 95% confidence interval (CI): 2 center dot 46-7 center dot 80, P &lt; 0 center dot 0001], high lactate dehydrogenase (LDH) levels (&gt;5 mu kat/l; OR 2 center dot 07, 95% CI: 1 center dot 51-2 center dot 84, P &lt; 0 center dot 0001), extensive osteolytic activity (OR 2 center dot 21, 95% CI: 1 center dot 54-3 center dot 15, P &lt; 0 center dot 001), and immunoglobulin A (IgA; OR 1 center dot 53, 95% CI: 1 center dot 11-2 center dot 11, P = 0 center dot 009) or the non-secretory type of MM (OR 2 center dot 83; 95% CI: 1 center dot 32-6 center dot 04, P = 0 center dot 007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression-free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13 center dot 8 months (95% CI: 11 center dot 4-16 center dot 3) vs 18 center dot 8 months (95% CI: 17 center dot 7-19 center dot 9), P = 0 center dot 006; mOS: 26 center dot 7 months (95% CI: 18 center dot 1-35 center dot 4) vs 58 center dot 7 months (95% CI: 54 center dot 8-62 center dot 6), P &lt; 0 center dot 001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/NV17-29343A" target="_blank" >NV17-29343A: Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

British Journal of Haematology

ISSN

0007-1048

e-ISSN

1365-2141

Svazek periodika

196

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

954-962

Kód UT WoS článku

000713664200001

EID výsledku v databázi Scopus

2-s2.0-85118348754